Guardant Health reported preliminary fourth-quarter revenue of roughly $280 million, a 39% increase year over year driven by higher volumes in oncology testing and rapid uptake of its Shield screening test. The company expects significant year-over-year growth in both oncology test volumes and Shield screening tests for the full year 2025. Guardant’s results highlight continued commercialization momentum for liquid biopsy screening and precision oncology assays. The firm also reported a strong cash position, indicating runway to support further test commercialization and potential international expansion.